Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time | Zendy

Matthew R. Smith | Zendy; Fred Saad | Zendy; Stéphane Oudard | Zendy; Neal D. Shore | Zendy; Karim Fizazi | Zendy; Paul Sieber | Zendy; Bertrand Tombal | Zendy; Ronaldo Damião | Zendy; Gavin Marx | Zendy; Kurt Miller | Zendy; Peter J. Van Veldhuizen | Zendy; Juan Moróte | Zendy; Zhishen Ye | Zendy; Roger Dansey | Zendy; Carsten Goessl | Zendy

Open Access

Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time

Author(s) -

Matthew R. Smith,

Fred Saad,

Stéphane Oudard,

Neal D. Shore,

Karim Fizazi,

Paul Sieber,

Bertrand Tombal,

Ronaldo Damião,

Gavin Marx,

Kurt Miller,

Peter J. Van Veldhuizen,

Juan Moróte,

Zhishen Ye,

Roger Dansey,

Carsten Goessl

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.44.6716

Subject(s) - denosumab , medicine , prostate cancer , hazard ratio , doubling time , bone metastasis , prostate specific antigen , urology , metastasis , prostate , oncology , cancer , surgery , osteoporosis , confidence interval , biochemistry , in vitro , chemistry

Denosumab, an anti-RANK ligand monoclonal antibody, significantly increases bone metastasis-free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant prostate cancer (CRPC) and baseline prostate-specific antigen (PSA) ≥ 8.0 ng/mL and/or PSA doubling time (PSADT) ≤ 10.0 months. To identify men at greatest risk for bone metastasis or death, we evaluated relationships between PSA and PSADT with BMFS in the placebo group and the efficacy and safety of denosumab in men with PSADT ≤ 10, ≤ 6, and ≤ 4 months.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research